Genesis Drug Discovery & Development, a Hamilton-based clinical contract research organization under the Genesis Biotechnology Group umbrella, announced Tuesday it has acquired New England Discovery Partners, a contract research organization specializing in synthetic and medicinal chemistry.
The acquisition of NEDP’s chemistry service portfolio will provide GD3 the ability to expand on its pre-clinical drug research and discovery services.
“We’re committed to building an industry-leading, fully integrated drug discovery CRO,” Dr. Eli Mordechai, CEO of GBG, said. “Adding NEDP is another way to differentiate our capabilities in the early drug discovery space. We’re significantly enhancing our portfolio around organic and medical chemistry to better serve our industry partners.”
